Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

AMACR Antikörper

AMACR Reaktivität: Human WB, IHC, ELISA, ICC Wirt: Maus Monoclonal 2A10F3 unconjugated
Produktnummer ABIN968957
  • Target Alle AMACR Antikörper anzeigen
    AMACR (alpha-Methylacyl-CoA Racemase (AMACR))
    Reaktivität
    • 96
    • 15
    • 11
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    Human
    Wirt
    • 62
    • 34
    • 2
    Maus
    Klonalität
    • 51
    • 47
    Monoklonal
    Konjugat
    • 57
    • 7
    • 7
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser AMACR Antikörper ist unkonjugiert
    Applikation
    • 64
    • 48
    • 35
    • 33
    • 18
    • 15
    • 11
    • 10
    • 7
    • 6
    • 6
    • 5
    • 3
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunocytochemistry (ICC)
    Verwendungszweck
    AMACR Antibody
    Aufreinigung
    Ascitic fluid
    Immunogen
    Purified recombinant fragment of human AMACR expressed in E. Coli.
    Klon
    2A10F3
    Isotyp
    IgG2b
    Top Product
    Discover our top product AMACR Primärantikörper
  • Applikationshinweise

    ELISA: 1/10000

    ICC: 1/200 - 1/1000

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Ascitic fluid containing 0.03 % sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
  • Chen, Watson, Marengo, Decker, Coleman, Nelson, Sikes: "Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo." in: Cancer letters, Vol. 244, Issue 2, pp. 274-88, (2006) (PubMed).

    Epstein, Herawi: "Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care." in: The Journal of urology, Vol. 175, Issue 3 Pt 1, pp. 820-34, (2006) (PubMed).

  • Target
    AMACR (alpha-Methylacyl-CoA Racemase (AMACR))
    Andere Bezeichnung
    AMACR (AMACR Produkte)
    Hintergrund

    Description: AMACR (alpha-methylacyl-CoA racemase) has been recently described as prostate cancer-specific gene that encodes a protein involved in the beta-oxidation of branched chain fatty acids. Expression of AMACR protein is found in prostatic adenocarcinoma but not in benign prostatic tissue. It stains premalignant lesions of prostate: high-grade prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia. AMACR can be used as a positive marker for PIN. Defects in AMACR are the cause of congenital bile acid synthesis defect type 4 (CBAS4), also known as cholestasis, intrahepatic, with defective conversion of trihydroxycoprostanic acid to cholic acid or trihydroxycoprostanic acid in bile. Clinical features include neonatal jaundice, intrahepatic cholestasis, bile duct deficiency and absence of cholic acid from bile.

    Aliases: RACE

    Molekulargewicht
    42kDa
    Gen-ID
    23600
    HGNC
    23600
    UniProt
    Q9UHK6
    Pathways
    Monocarboxylic Acid Catabolic Process
Sie sind hier:
Kundenservice